A Comparison of the Efficacy and Toxic Effects of Sustained-vs Immediate-Release Niacin in Hypercholesterolemic Patients

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 9, 1994, Pages 672-677

  Mckenney, James M ^a   Proctor, Jack D ^a   Harris, Scott ^b   Chinchili, Vernon M ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Baptist Health Medical Center Little Rock   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID;

ACANTHOSIS NIGRICANS; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMPARISON; DRUG DOSE; DRUG EFFICACY; DRUG RELEASE; DRUG THERAPY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MALE; PHARMACOLOGY; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0028057319     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510330050033     Document Type: Article

References (43)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
2. Christensen AN, Achor RWP, Berge KG, Mason HL. Nicotinic acid treatment of hypercholesterolemia. JAMA. 1961;177:546-550.
3. Berge KG, Achor RWP, Christensen NA, Nason HL, Barker NW. Hypercholesterolemia and nicotinic acid. Am J Med. 1961;31:24-35.
4. Knopp RH, Ginsbert J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemia subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-650.
5. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol. 1989;64:725-729.
6. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992;95:69-76.
7. Carlson LS, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
8. Tornvall P, Hamsten A, Johansson J, Carlson LA. Normalization of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid. Atherosclerosis. 1990;84:219-227.
9. King JM, Miller NE, Crouse JR. Effects of niacin on fasting and postprandial lipids in normolipidemic low HDL subjects. Arteriosclerosis. 1991;11:1519a.
10. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 1992;69:1083-1085.
11. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
12. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
13. Brown BG, Lin JT, Schaefer SM, Kaplan CA, Dodge HY, Albers JJ. Niacin or lovastatin, combined with colestipol, regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoprotein B. Circulation. 1989;80:II-266.
14. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-1298.
15. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary arteriosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
16. Luria MH. Effect of low-dose niacin on high density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. Arch Intern Med. 1988;148:2493-2495.
17. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang Z, Ripsin CM. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424-1432.
18. Knapp TRF, Middleton RK. Adverse effects of sustained-release niacin. Ann Pharmacotherapy. 1991;25:253-254.
19. Clementz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol. 1987;9:582-584.
20. Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA. 1990; 264:241-243.
21. Palumbo PJ. Rediscovery of crystalline niacin. Mayo Clin Proc. 1991;66:112-113.
22. Frost PH. All niacin is not the same. Ann Intern Med. 1991;114:1065.
23. Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc. 1991; 66:23-28.
24. Mullin GE, Greenson JK, Mitchel MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med. 1989;111: 253-255.
25. Knopp RH. Niacin and hepatic failure. Ann Intern Med. 1991;111:769.
26. Goldstein MR. Potential problems with the widespread use of niacin. Am J Med. 1988;85:881.
27. Ferenchick G, Rovner D. Case report: hepatitis and hematemesis complicating nicotinic acid use. Am J Med Sci. 1989;298:191-193.
28. Hodis HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. JAMA. 1990;264:181.
29. Patterson DJ, Dew EW, Gyorkey R, Graham GY. Niacin hepatitis. South Med J. 1983;76:239-241.
30. Einstein N, Baker A, Galper J, Wolfe H. Jaundice due to nicotinic acid therapy. Dig Dis. 1975; 20:282-286.
31. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med. 1992; 93:102-104.
32. Remmell PS, Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). J Am Diet Assoc. 1980;76:351-356.
33. Woolson RF. The Analysis of Biomedical Data. New York, NY: John Wiley & Sons Inc; 1987:161-162.
34. National Institutes of Health. Lipid and lipoprotein analysis. In: Manual of Laboratory Operations: Lipid Research Clinics Program, Vol. I. US Dept of Health and Human Services; May 1974:56.
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem. 1972;18:499-552.
36. Current status of blood cholesterol measurements in clinical laboratories in the United States: a report from the Laboratory Standardization Panel of the National Cholesterol Education Program. Clin Chem. 1988;34:193-210.
37. Jennrich RI, Schluchter MC. Unbalanced repeated measures models with structured covariance matrices. Biometrics. 1986;42:805-820.
38. Morrison DF. Multivariate Statistical Methods. 2nd ed. New York, NY: McGraw-Hill International Book Co; 1976:102-111.
39. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
40. Keenan JM, Bae CY, Fontaine PL, et al. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained release niacin. J Am Geriatr Soc. 1991;40:12-18.
41. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77-81.
42. Henkin Y, Oberman A. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med. 1991;91:239-246.
43. Kahn SE, Beard JC, Schwartz MW, et al. Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38:562-568.